Le Lézard
Classified in: Health, Business
Subjects: NEW PRODUCTS/SERVICES, BUSINESS CONTRACTS

Pure Extracts Receives Purchase Order for a New Listing of Cured Resin Vape Carts from the Ontario Cannabis Store


VANCOUVER, British Columbia, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) ("Pure Extracts" or the "Company"), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has received a purchase order (PO) from the Ontario Cannabis Store (OCS) for its new, cured resin, 1 g vape carts. This Pure PullsTM branded product called Durga Mata Cured Resin will be available in October for purchase through licensed retailers throughout the province of Ontario, and through the OCS' online store.

Cured resin is a cannabis concentrate derived from dried and cured cannabis plant material. The drying and curing process removes moisture from the buds and improves the flavour and aroma of the final product. The cannabis plant material then undergoes an extraction process to produce a cured resin vape oil.

The specialized extraction techniques used to create Pure Pulls Durga Mata Cured Resin retains all the natural terpenes and the nice earthy flavour to ensure a smooth, enjoyable vaping experience every time.

Pure Extracts' CEO, Ben Nikolaevsky, remarked, "We are excited about receiving a PO for our newest product category - cured resins. And it's especially gratifying to have received this PO from the OCS, in the largest and most competitive provincial cannabis market in Canada. This marks another successful milestone in the expansion of our line of branded products."

About Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)
Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company's stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
[email protected]

ON BEHALF OF THE BOARD
"Ben Nikolaevsky"
Ben Nikolaevsky
CEO and Director

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts', are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company's expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under "Risk Factors" in the Company's Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.



These press releases may also interest you

at 14:56
Cymbiotika has been named a silver winner in Small Company of The Year in Best in Biz Awards, the only independent business awards program judged each year by prominent editors and reporters from top-tier publications in North America. Last year,...

at 14:45
The "Global Flow Cytometry Market Size, Share & Industry Trends Analysis Report By Application (Academic & Clinical and Diagnostic), By End User, By Technology (Cell Based and Bead Based), By Component, By Regional Outlook and Forecast, 2022 - 2028"...

at 14:35
Leadership from Allegheny Health Network's (AHN) Women's Institute, AHN West Penn and Development Office honored one local family Tuesday afternoon with a plaque presentation to mark the official opening of the hospital's Butterfly Suite....

at 14:30
The "Tuberculosis Diagnostics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to  ResearchAndMarkets.com's offering. This report...

at 14:30
Stay on top of current hot topics through free webinars presented by leading experts in the pharma,...

at 14:25
Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment, announced today that it has received Registration Approval from the Pharmaceutical and Herbal Medicines Registration and Control Administration (Drug and Food Control) of the...



News published on 5 october 2022 at 08:45 and distributed by: